Thermo Fisher Scientific (TMO) Cash from Investing Activities (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Cash from Investing Activities for 18 consecutive years, with $164.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Investing Activities rose 156.94% year-over-year to $164.0 million; the trailing twelve-month figure through Jun 2026 stood at -$12.0 billion (down 175.07% YoY), and the FY2025 full-year result was -$4.0 billion, up 30.71% from the prior year.
• Cash from Investing Activities climbed to $164.0 million in Q2 2026 per TMO's latest filing, from -$9.0 billion in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $891.0 million in Q4 2025 and bottomed at -$9.0 billion in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$1.4 billion across 5 years, with a median of -$526.0 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities soared 4355.0% in 2025, then slumped 1600.38% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$525.0 million in 2022, then increased by 28.38% to -$376.0 million in 2023, then jumped by 105.32% to $20.0 million in 2024, then jumped by 4355.0% to $891.0 million in 2025, then plunged by 81.59% to $164.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $164.0 million, -$9.0 billion, and $891.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.